Moderna
MRNA
136 hedge funds and large institutions have $2.68B invested in Moderna in 2019 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 36 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 30
61% more call options, than puts
Call options by funds: $17.7M | Put options by funds: $10.9M
28% more capital invested
Capital invested by funds: $2.1B → $2.68B (+$587M)
7.51% more ownership
Funds ownership: 43.55% → 51.06% (+7.5%)
0% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 36
1% less funds holding
Funds holding: 138 → 136 (-2)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$245M |
| 2 |
BlackRock
New York
|
+$114M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.2M |
| 5 |
TP
Theleme Partners
London,
United Kingdom
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$52M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.3M |
| 3 |
JP Morgan Chase
New York
|
-$15.4M |
| 4 |
RWA
Ropes Wealth Advisors
Boston,
Massachusetts
|
-$12.2M |
| 5 |
Neuberger Berman Group
New York
|
-$11.1M |
MRNA Hedge Fund Activity: Q3 2019 in Review
136 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q3 2019, worth a combined $2.68B — up 28% from $2.1B a quarter earlier.
Fund positioning in MRNA was balanced in Q3 2019: 36 funds opened new positions, 36 closed out, 55 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $245M. The largest seller was Viking Global Investors, cutting an estimated $52M.
- 136 institutional investors held Moderna (MRNA) as of Q3 2019, down from 138 in Q2 2019.
- Funds reported $2.68B of Moderna stock for Q3 2019, up 28% quarter-over-quarter.
- 36 funds opened new Moderna positions in Q3 2019 and 36 closed out, a net change of 0 holders.
- The largest Moderna buyer in Q3 2019 was Vanguard Group, an estimated $245M added.
- The largest Moderna seller in Q3 2019 was Viking Global Investors, an estimated $52M sold.
Based on aggregated 13F filings for Q3 2019.